EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022



Summary



Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a multi-factorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. It results in symptoms of discomfort such as visual disturbance and tear film instability (DEWS, 2007). Middle-aged and older adults are the most commonly affected group because of the high prevalence of contact lens usage, systemic drug effects, autoimmune diseases, and refractive surgeries in these group (Davis, 2003; Glasson et al., 2003; Schaumberg et al., 2002; Schaumberg et al., 2003; Toda et al., 2001).

Globally, dry eye has a prevalence of up to 33% (Clegg et al., 2006; Lemp et al., 2008; Schaumberg et al., 2002; Shimmura et al., 1999). The prevalence of dry eye is estimated to range from <0.1% to 33% across different countries and varies between 5% to >30% in various ages groups worldwide (Clegg et al., 2006; Lemp et al., 2008; Shimmura et al., 1999). Research also shows that dry eye syndrome is more prevalent in women than in men (Schaumberg et al., 2002).



Scope


- The Dry Eye Syndrome, EpiCast Report provides an overview of the risk factors and global trends of dry eye syndrome in the nine major markets (US, France, Germany, Italy, Spain, UK, Japan, China, and India).
- It also includes a 10-year epidemiology forecast of the prevalent cases of dry eye syndrome, segmented by age (given in five-year increments beginning at age 45 years and ending at ages 85 years and older), sex, and severity in these markets.



Reasons to buy


- Develop business strategies by understanding the trends shaping and driving the global dry eye syndrome market.
- Quantify patient populations in the global dry eye syndrome market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups, sex, and severity levels that present the best opportunities for dry eye syndrome therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 7
3 Epidemiology 8
3.1 Risk Factors and Comorbidities 8
3.1.1 Risk of dry eye syndrome increases 35% each decade after age 40 9
3.1.2 Women are twice as likely to have dry eye syndrome as men 9
3.1.3 Use of certain medications may increase the risk of developing dry eye syndrome 10
3.1.4 Diets rich in omega-3 fatty acid may prevent dry eye syndrome 11
3.1.5 Certain environmental conditions can double the risk of dry eye syndrome 11
3.2 Global Trends 12
3.2.1 US 12
3.2.2 5EU 12
3.2.3 Asia 13
3.3 Forecast Methodology 14
3.3.1 Sources used 14
3.3.2 Forecast Assumptions and Methods 17
3.3.3 Sources Not Used 19
3.4 Epidemiology Forecast (2012-2022) 19
3.4.1 Prevalent Cases of Dry Eye Syndrome 19
3.4.2 Age-Specific Prevalent Cases 21
3.4.3 Sex-Specific Prevalent Cases 22
3.4.4 Age-Standardized Prevalence of Dry Eye Syndrome 24
3.4.5 Prevalent Cases of Dry Eye Syndrome by Severity 25
3.5 Discussion 27
3.5.1 Conclusions on Epidemiology Trends 27
3.5.2 Limitations of Analysis 29
3.5.3 Strengths of Analysis 29
4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 33
4.2.1 Epidemiologists 33
4.2.2 Reviewers 34
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 35
4.2.4 Global Head of Healthcare 36
4.3 About GlobalData 36
4.4 About EpiCast 37
4.5 Contact Us 37
4.6 Disclaimer 37



List of Tables

Table 1: Risk Factors and Comorbidities for Dry Eye Syndrome 8
Table 2: Sources of Epidemiology Data Used for the Forecast 14
Table 3: 9MM, Prevalent Cases of Dry Eye Syndrome, Ages ?45 Years, Men and Women, N (Millions), 2012-2022 20
Table 4: 9MM, Prevalent Cases of Dry Eye Syndrome, By Age, Men and Women, N (Millions) (Row %), 2012 21
Table 5: 9MM, Prevalent Cases of Dry Eye Syndrome, By Sex, Ages ?45 Years, N (Millions) (Row %), 2012 23
Table 6: 9MM, Prevalent Cases of Dry Eye Syndrome, By Severity, Ages ?45 Years, N (Millions) (Row %), 2012 26



List of Figures

Figure 1: 9MM, Prevalent Cases of Dry Eye Syndrome, Ages ?45 Years, Men and Women, N (Millions), 2012-2022 20
Figure 2: 9MM, Prevalent Cases of Dry Eye Syndrome, By Age, N (Millions), 2012 22
Figure 3: 9MM, Prevalent Cases of Dry Eye Syndrome, By Sex, Ages ?45 Years, N (Millions), 2012 23
Figure 4: 9MM, Age-Standardized Prevalence of Dry Eye Syndrome, Ages ?45 Years, By Sex, 2012 25
Figure 5: 9MM, Prevalent Cases of Dry Eye Syndrome, By Severity, Ages ?45 Years, N (Millions), 2012 26

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 7 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

1 Companies

Company Profiles

CytRx Corp.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.